SCHEMBL4236479

SCHEMBL4236479

CCC(CC)NC(=O)Nc1ccc(Oc2ccc(NC(=O)c3ccc(OC45CCCC(CC4)N5)cc3)cc2)c(OC)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.42
RAB9A P51151 3/20 0.41
NPC1 O15118 2/20 0.41
ALDH1A1 P00352 1/20 0.41
TP53 P04637 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MCHR1 Q99705 5/20 0.40
NAMPT P43490 1/20 0.40
TAS1R3 Q7RTX0 1/20 0.39
TAS1R1 Q7RTX1 1/20 0.39
FGFR1 P11362 1/20 0.39
KMT2A Q03164 5/20 0.38
MEN1 O00255 4/20 0.38
KDM4E B2RXH2 1/20 0.38
GAA P10253 2/20 0.37
MAPT P10636 2/20 0.37
CASP3 P42574 1/20 0.37
SENP7 Q9BQF6 1/20 0.37
HTT P42858 1/20 0.37
HPGD P15428 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4744162 0.89 MCHR1 (0.37) PKMRAB9ANPC1ALDH1A1TP53
SCHEMBL4228457 0.88 PKM (0.35) PKMRAB9ANPC1ALDH1A1TP53
SCHEMBL4234105 0.82 PKM (0.47) PKMRAB9ANPC1ALDH1A1TP53
SCHEMBL4229247 0.81 MCHR1 (0.45) PKMRAB9ANPC1ALDH1A1TP53
SCHEMBL4240029 0.81 MCHR1 (0.43) PKMRAB9ANPC1ALDH1A1TP53
SCHEMBL4237916 0.81 PKM (0.45) PKMRAB9ANPC1ALDH1A1TP53
SCHEMBL4229361 0.81 MCHR1 (0.42) PKMRAB9ANPC1ALDH1A1TP53
SCHEMBL4233531 0.81 MCHR1 (0.44) PKMRAB9ANPC1ALDH1A1TP53
SCHEMBL4228419 0.80 MCHR1 (0.41) PKMRAB9ANPC1ALDH1A1TP53
SCHEMBL4228607 0.80 MCHR1 (0.42) PKMRAB9ANPC1ALDH1A1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US claimed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
EP-1879887-A2 NPY ANTAGONISTS, PREPARATION AND USE Cerep (FR) 2008-01-23 EP disclosed
WO-2006108965-A2 NPY ANTAGONISTS, PREPARATION AND USE CEREP (FR) 2006-10-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233910-A1 Npy antagonists, preparation and uses NPY1R, NPY5R, NPY2R PKM 1734/4885RAB9A 2492/4885NPC1 2338/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.